Evaluation of Geistlich Fibro-Gide® in Comparison to CTG for the Treatment Around Implants

This double blind, randomized, parallel study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for soft tissue volume augmentation around dental implants

Inclusion Criteria: * Subjects requiring soft tissue augmentation around single implants, i.e., thin biotype with potential for * All implants must be at least 6 months post bone graft/implant placement * have at least 1 mm of keratinized tissue width (KTw), * have final restoration permanently in place for at least 4-weeks and * subject have no recession on the implant body * Subjects who, can achieve good oral hygiene (80% plaque free surfaces on the implant and maintain 80% plaque free surfaces on teeth adjacent to treatment sites). Exclusion Criteria: * participation within the last six months in other interventional studies. * any systemic condition that could influence healing, such as uncontrolled diabetes mellitus - confirmed by A1C score ≥7% - cancer, HIV, oral muco- cutaneous conditions and drug induced gingival enlargement. * taking medications that compromise wound healing, such as chronic steroid use - either inhaler or systemic, calcium channel blockers with secondary hyperplastic tissue reactions, anti-seizure medications, IV bisphosphates for bone metabolic diseases, radiation or other immuno-suppressive therapy. * acute infectious lesions in the areas intended for surgery. * History within the last 6 months of weekly or more frequent use of nicotine products * Female subjects who are pregnant or lactating, or sexually active female subjects who are of childbearing potential and who are not using hormonal or barrier methods of birth control * Untreated, moderate to severe periodontal disease.